FDA approves subcutaneous injectable for myasthenia gravis
Drug Discovery World
JUNE 23, 2023
We are pleased that argenx has received FDA approval for the subcutaneous form of efgartigimod, which reinforces their commitment to the patient community with a broadening of treatment options that brings flexibility for patients,” said Dr Helen Torley, President and Chief Executive Officer of Halozyme. “We
Let's personalize your content